Trade secret theft is on the rise, and biotechnology and pharmaceutical companies are particularly at risk. As courts continue to narrow the scope of patent rights (as they’ve done with Alice Corp. v. CLS Bank International, Association for Molecular Pathology v. Myriad Genetics and Mayo Collaborative Services v. Prometheus Laboratories) and biopharma expands its focus on outsourcing and strategic deals, securing intellectual property assets through trade secret protection has never been more critical.
Risky Business
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
